{"id":5848,"date":"2020-12-21T00:00:00","date_gmt":"2020-12-21T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/12\/21\/early-onset-crc-incidence-examined-by-histologic-subtype\/"},"modified":"2020-12-23T16:10:26","modified_gmt":"2020-12-23T16:10:26","slug":"early-onset-crc-incidence-examined-by-histologic-subtype","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/12\/21\/early-onset-crc-incidence-examined-by-histologic-subtype\/","title":{"rendered":"Early-Onset CRC Incidence Examined by Histologic Subtype"},"content":{"rendered":"<h3>\n<p>Adenocarcinomas increasing in most early-onset subgroups; carcinoid tumors increasing more steeply in all age groups<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Dec. 21, 2020 (HealthDay News) &#8212; Among individuals with early-onset colorectal cancer (EOCRC), adenocarcinoma rates are increasing in specific subgroups, but carcinoid tumors are increasing more steeply in all age groups, according to a study published online Dec. 15 in the <em>Annals of Internal Medicine<\/em>.<em><\/em><\/p>\n<p>Eric M. Montminy, M.D., from the Tulane University School of Medicine in New Orleans, and colleagues examined the incidence rates (IRs) of EOCRC and changes in IR over time in a retrospective analysis using Surveillance, Epidemiology, and End Results 18 data from 2000 to 2016 for 119,624 patients with CRC.<\/p>\n<p>The researchers found that the steepest changes in adenocarcinoma three-year moving average IRs were seen for rectal-only cases in those aged 20 to 29 and 30 to 39 years and colon-only cases in those aged 30 to 39 years (+39, +39, and +20 percent, respectively), corresponding to annual percent changes of 1.6, 2.2, and 1.2 percent, respectively. The three-year moving average IRs increased in colon-only and rectal-only subsites among those aged 40 to 49 years (+13 and +16 percent, respectively). Carcinoid tumors were common and accounted for 4 to 20 percent of colorectal cancer cases and 8 to 34 percent of rectal cancer cases. Colon-only carcinoid tumors were rarely observed. In all age groups, colorectal carcinoid tumor IRs increased more steeply than adenocarcinomas.<\/p>\n<p>&#8220;These findings underscore the importance of assessing histologic CRC subtypes independently,&#8221; the authors write. &#8220;This approach may lead to a better understanding of the drivers of temporal changes in overall CRC incidence.&#8221;<\/p>\n<p>Two authors disclosed financial ties to Exact Sciences, a molecular diagnostics company.<\/p>\n<p><a href=\"https:\/\/www.acpjournals.org\/doi\/10.7326\/M20-0068\" target=\"_blank\" rel=\"noopener noreferrer\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/www.acpjournals.org\/doi\/10.7326\/m20-7244\" target=\"_blank\" rel=\"noopener noreferrer\">Editorial  (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adenocarcinomas increasing in most early-onset subgroups; carcinoid tumors increasing more steeply in all age groups<\/p>\n","protected":false},"author":4,"featured_media":6100,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[364,322],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/5848"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=5848"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/5848\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/6100"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=5848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=5848"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=5848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}